{
 "id": "epb64cnnc0",
 "slug": "ibrutinib-regimen",
 "title": "Ibrutinib regimen",
 "updated": "2026-10-15",
 "topic_path": [
  {
   "id": "life",
   "label": "Life and health",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life"
  },
  {
   "id": "life.health",
   "label": "Human health and medicine",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health"
  },
  {
   "id": "life.health.medicines",
   "label": "Medicines and therapeutics",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines"
  },
  {
   "id": "life.health.medicines.cancer-chemotherapy",
   "label": "Cancer chemotherapy and regimens",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy"
  },
  {
   "id": "life.health.medicines.cancer-chemotherapy.targeted-agent-regimens",
   "label": "Targeted agent regimens",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy.targeted-agent-regimens"
  }
 ],
 "geo": [
  {
   "id": "geo.nongeo.t2001.life.health.medicines.cancer-chemotherapy",
   "label": "Non-geographic · 2001 to 2020: Cancer chemotherapy and regimens",
   "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health.medicines.cancer-chemotherapy",
   "path": [
    {
     "id": "geo.nongeo",
     "label": "Non-geographic",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo"
    },
    {
     "id": "geo.nongeo.t2001",
     "label": "Non-geographic · 2001 to 2020",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001"
    },
    {
     "id": "geo.nongeo.t2001.life",
     "label": "Life and health",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life"
    },
    {
     "id": "geo.nongeo.t2001.life.health",
     "label": "Human health and medicine",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health"
    },
    {
     "id": "geo.nongeo.t2001.life.health.medicines",
     "label": "Medicines and therapeutics",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health.medicines"
    },
    {
     "id": "geo.nongeo.t2001.life.health.medicines.cancer-chemotherapy",
     "label": "Cancer chemotherapy and regimens",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health.medicines.cancer-chemotherapy"
    }
   ]
  }
 ],
 "excerpt": "The ibrutinib regimen is a combination treatment for primary central nervous system lymphoma in which the BTK inhibitor ibrutinib is given with high-dose methotrexate, usually with rituximab.",
 "snippet": "The ibrutinib regimen is a combination treatment for primary central nervous system lymphoma in which the BTK inhibitor ibrutinib is given with high-dose methotrexate, usually with rituximab.",
 "node": "life.health.medicines.cancer-chemotherapy.targeted-agent-regimens",
 "markdown": "# Ibrutinib regimen\n\nThe ibrutinib regimen is a combination treatment for primary central nervous system lymphoma (PCNSL) in which the Bruton tyrosine kinase (BTK) inhibitor ibrutinib is given with high-dose methotrexate (HD-MTX), usually with rituximab, and sometimes with additional cytotoxic drugs. It has been studied in newly diagnosed PCNSL, relapsed or refractory PCNSL, secondary CNS lymphoma, and primary vitreoretinal lymphoma.<sup>[1](https://pubmed.ncbi.nlm.nih.gov/30567753/)</sup><sup> • </sup><sup>[2](https://ichgcp.net/clinical-trials-registry/NCT02315326)</sup><sup> • </sup><sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup>\n\n| Key fact | Detail |\n|---|---|\n| Core drugs | Ibrutinib 560 or 840 mg daily, HD-MTX 3.5 g/m², rituximab 500 mg/m²<sup>[1](https://pubmed.ncbi.nlm.nih.gov/30567753/)</sup> |\n| Phase 1b combination trial | Relapsed/refractory CNS lymphoma: ORR 80% (12/15), median PFS 9.2 months<sup>[1](https://pubmed.ncbi.nlm.nih.gov/30567753/)</sup><sup> • </sup><sup>[4](https://ma1.mdedge.com/content/ibrutinib-mtx-rituximab-combo-shows-promise-cns-lymphoma)</sup> |\n| CNS penetration | CSF/plasma ibrutinib AUC ratio 0.78% at 840 mg; 28.7% after correcting for 97.3% protein binding<sup>[5](https://www.sciencedirect.com/science/article/pii/S153560817301678)</sup> |\n| Newly diagnosed, triple IRM | 5-year OS and PFS both 77.8% at median follow-up 77.6 months<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup> |\n| MIT variant (rituximab-free) | Best ORR 93.9%, CR 72.7%, 2-year PFS 57.6%, 2-year OS 84.8%<sup>[6](https://aacrjournals.org/bloodcancerdiscov/article/6/3/191/762115/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide)</sup> |\n| R-MPV/i variant | CR rate 97%, 2-year PFS 84.2% in newly diagnosed PCNSL<sup>[7](https://www.hematologyadvisor.com/news/lymphoma-pcnsl-ibrutinib-rmvp-deep-durable-response-treatment-risk/)</sup> |\n| Notable toxicities | Atrial fibrillation 3–7%, subdural hematoma 6%, invasive aspergillosis risk<sup>[8](https://ash.confex.com/ash/2023/webprogram/Paper185212.html)</sup><sup> • </sup><sup>[6](https://aacrjournals.org/bloodcancerdiscov/article/6/3/191/762115/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide)</sup> |\n\n## How it works\n\nIbrutinib irreversibly inhibits BTK, a kinase in B-cell receptor signaling downstream of MYD88 and CD79B. As a single agent it crosses the blood–brain barrier and produces responses, but these are incomplete and transient, lasting about 6 months, which motivates combination therapy.<sup>[9](https://www.ovid.com/journals/camed/fulltext/10.1002/cam4.3499~clinical-outcomes-of-newly-diagnosed-primary-cns-lymphoma)</sup> Penetration data support CNS activity: at 840 mg the median CSF/plasma AUC ratio was 0.78% (range 0.62%–1.25%), rising to 28.7% (23.2%–44.6%) when corrected for 97.3% protein binding, and CSF concentrations exceeded the enzymatic IC50 of 0.5 nM for a median of 4 hours.<sup>[5](https://www.sciencedirect.com/science/article/pii/S153560817301678)</sup>\n\nPreclinical work suggests synergy between ibrutinib and HD-MTX through inhibition of breast cancer resistance protein (BCRP), which enhances systemic MTX exposure.<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup> Sustained tumor responses in the phase 1b trial were associated with clearance of circulating tumor DNA from the CSF, a monitoring correlate also seen in the MIT trial (P = 0.044 for longer PFS).<sup>[1](https://pubmed.ncbi.nlm.nih.gov/30567753/)</sup><sup> • </sup><sup>[6](https://aacrjournals.org/bloodcancerdiscov/article/6/3/191/762115/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide)</sup>\n\n## How it is done\n\nIn the phase 1b trial (NCT02315326), HD-MTX 3.5 g/m² with standard hydration and leucovorin support was given on days 1 and 15 of each 28-day cycle for 4 cycles (8 administrations), with rituximab 500 mg/m² on days 0, 14, and 28 of cycle 1. Ibrutinib 560 mg daily was given on days 5–14 and 19–28, and continued daily after HD-MTX completion; it was deliberately not administered concurrently with HD-MTX to minimize drug–drug interaction, and dose escalation tested 560 and 840 mg.<sup>[2](https://ichgcp.net/clinical-trials-registry/NCT02315326)</sup>\n\nLater regimens tie the restart to a methotrexate level. In the IRM pilot, rituximab 375 mg/m² was given on day 0, HD-MTX 3.5 g/m² over 3 hours on day 1, and ibrutinib 560 mg daily oral started once plasma MTX fell below 0.1 µmol/L, in 28-day cycles.<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup> In the MIT regimen, MTX 3.5 g/m² was infused over 6 hours on day 1 with calcium folinate 15 mg/m² every 6 hours for 12 hours after infusion until clearance; temozolomide 150 mg/m² was given on days 1–5 and ibrutinib 560 mg after HD-MTX clearance until day 21, repeated every 3 weeks for up to six courses.<sup>[6](https://aacrjournals.org/bloodcancerdiscov/article/6/3/191/762115/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide)</sup> Induction is typically followed by consolidation (autologous stem-cell transplant or additional cycles) and ibrutinib maintenance, often 560 mg daily for up to 2 years.<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup>\n\n## Origin\n\nThe biological foundation came from a preclinical study showing that ibrutinib targets BTK signaling critical to PCNSL, published in Cancer Discovery in 2017 by Christian Grommes and colleagues.<sup>[10](https://doi.org/10.1158/2159-8290.cd-17-0613)</sup> In the same year, [Michail S. Lionakis](https://www.edgepedia.org/michail-s-lionakis) and colleagues reported ibrutinib monotherapy activity in PCNSL and the DA-TEDDi-R combination in Cancer Cell.<sup>[11](https://doi.org/10.1016/j.ccell.2017.04.012)</sup> The combination of ibrutinib with HD-MTX and rituximab was first reported in the phase 1b trial led by Christian Grommes and colleagues, published in Blood in 2018 and registered as NCT02315326.<sup>[12](https://doi.org/10.1182/blood-2018-09-875732)</sup><sup> • </sup><sup>[2](https://ichgcp.net/clinical-trials-registry/NCT02315326)</sup> That trial built on the earlier R-MPV induction regimen of rituximab, methotrexate, procarbazine, and vincristine reported by Patrick G. Morris and colleagues in 2013 in the Journal of Clinical Oncology.<sup>[13](https://doi.org/10.1200/jco.2013.50.4910)</sup> Subsequent first-line combinations followed: the IRM pilot by Yixian Guo and colleagues (2025, Frontiers in Oncology),<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup> the MIT phase II study by Yan Gao and colleagues (2025, Blood Cancer Discovery),<sup>[14](https://doi.org/10.1158/2643-3230.bcd-24-0156)</sup> the R-MPV/i study by Lauren R. Schaff and colleagues in Neuro-Oncology,<sup>[15](https://doi.org/10.1093/neuonc/noag011)</sup> and the LOC-R01 phase IB/II by Marion Alcantara and colleagues (2024, [Journal of Hematology & Oncology](https://www.edgepedia.org/journal-of-hematology-and-oncology)).<sup>[16](https://doi.org/10.1186/s13045-024-01606-w)</sup>\n\n## Variants\n\n- **Ibrutinib monotherapy.** The iLOC phase II study gave ibrutinib 560 mg/day until progression to 52 patients with relapsed/refractory PCNSL or primary vitreoretinal lymphoma.<sup>[17](https://pubmed.ncbi.nlm.nih.gov/31279304/)</sup> Across prospective studies, monotherapy response rates in relapsed/refractory PCNSL were 42%–74% with CR rates of 19%–39% and median PFS 4.5–4.8 months.<sup>[6](https://aacrjournals.org/bloodcancerdiscov/article/6/3/191/762115/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide)</sup>\n- **Ibrutinib maintenance after HD-MTX.** A phase 2 study by Osnat Bairey and colleagues tested ibrutinib maintenance after first-line HD-MTX-based chemotherapy in elderly patients.<sup>[18](https://doi.org/10.1002/cncr.34985)</sup>\n- **IRM (triple ibrutinib–rituximab–MTX).** [Rituximab](https://www.edgepedia.org/rituximab) 375 mg/m² day 0, HD-MTX 3.5 g/m² day 1, ibrutinib 560 mg daily after MTX clearance.<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup>\n- **MIT (rituximab-free).** HD-MTX, ibrutinib, and temozolomide; rituximab was avoided in induction to minimize infection risk such as aspergillosis associated with BTK inhibitors.<sup>[6](https://aacrjournals.org/bloodcancerdiscov/article/6/3/191/762115/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide)</sup>\n- **R-MPV/i.** [Ibrutinib](https://www.edgepedia.org/ibrutinib) 560 mg on days 5–14 and 19–28 added to rituximab 500 mg/m² (days 0 and 14), MTX 3.5 g/m² (days 1 and 15), vincristine 1.4 mg/m², and procarbazine 100 mg/m² (days 1–7).<sup>[19](https://www.curetoday.com/view/imbruvica-plus-drug-combo-shows-strong-responses-in-newly-diagnosed-pcnsl)</sup>\n- **RMA plus ibrutinib.** Ibrutinib 560 mg/d added to rituximab–methotrexate–cytarabine, with thiotepa-conditioned autologous transplant and maintenance with ibrutinib or lenalidomide.<sup>[20](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1579483/full)</sup>\n\n## Applications\n\nIn relapsed/refractory disease, the phase 1b combination produced responses in 12 of 15 patients (80%) with no dose-limiting toxicity; at median follow-up 19.7 months, median PFS was 9.2 months and median OS was not reached, with 11 of 15 patients alive.<sup>[1](https://pubmed.ncbi.nlm.nih.gov/30567753/)</sup><sup> • </sup><sup>[4](https://ma1.mdedge.com/content/ibrutinib-mtx-rituximab-combo-shows-promise-cns-lymphoma)</sup> Adding rituximab to HD-MTX and ibrutinib raised the CR rate in relapsed/refractory CNS lymphoma from 33% to 56%.<sup>[9](https://www.ovid.com/journals/camed/fulltext/10.1002/cam4.3499~clinical-outcomes-of-newly-diagnosed-primary-cns-lymphoma)</sup>\n\nIn newly diagnosed disease, the IRM pilot (9 patients) achieved induction ORR 100% (CR 77.8%), post-consolidation CR 88.9%, and 5-year OS and PFS both 77.8%.<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup> The MIT phase II trial (33 analyzed) reached best ORR 93.9%, CR 72.7%, 2-year PFS 57.6% (95% CI 49.0–66.2), and 2-year OS 84.8% (95% CI 78.6–91.0).<sup>[6](https://aacrjournals.org/bloodcancerdiscov/article/6/3/191/762115/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide)</sup> R-MPV/i in 30 evaluable patients produced ORR 100% with overall CR rate 97% (95% CI 83.3–99.8%), no primary refractory disease, and 2-year PFS 84.2% (95% CI 62.7–93.9%) at median follow-up 32.1 months.<sup>[7](https://www.hematologyadvisor.com/news/lymphoma-pcnsl-ibrutinib-rmvp-deep-durable-response-treatment-risk/)</sup><sup> • </sup><sup>[19](https://www.curetoday.com/view/imbruvica-plus-drug-combo-shows-strong-responses-in-newly-diagnosed-pcnsl)</sup> In the retrospective RMA cohort of 88 patients, adding ibrutinib improved CR rate (41.4% vs 16.9%, P = 0.013), ORR (86.2% vs 59.3%, P = 0.011), and OS (P = 0.036), with 2-year PFS 56.7% and 3-year OS 75.1%.<sup>[20](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1579483/full)</sup>\n\n## Limitations and alternatives\n\nToxicity is the main constraint. In the MIT trial, grade ≥3 events occurred in 27.3% of patients, with four asymptomatic subdural hematomas (one surgically treated) and one atrial fibrillation during ibrutinib maintenance.<sup>[6](https://aacrjournals.org/bloodcancerdiscov/article/6/3/191/762115/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide)</sup> R-MPV/i showed thrombocytopenia in 100%, lymphopenia 97%, anemia 93%, atrial fibrillation 7%, and no [Aspergillus](https://www.edgepedia.org/aspergillus) or [Pneumocystis](https://www.edgepedia.org/pneumocystis) infections.<sup>[7](https://www.hematologyadvisor.com/news/lymphoma-pcnsl-ibrutinib-rmvp-deep-durable-response-treatment-risk/)</sup> By contrast, two patients developed pulmonary aspergillosis, one of them fatal, in the iLOC monotherapy study, and aspergillosis and pneumocystosis appeared among the dose-limiting toxicities in LOC-R01.<sup>[17](https://pubmed.ncbi.nlm.nih.gov/31279304/)</sup><sup> • </sup><sup>[16](https://doi.org/10.1186/s13045-024-01606-w)</sup> The IRM pilot saw grade ≥3 events limited to neutropenia, anemia, and one gastrointestinal hemorrhage with concomitant rivaroxaban.<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup>\n\nAgainst alternatives, the MATRix regimen (methotrexate–cytarabine–rituximab) achieved 7-year OS of 70% in IELSG32 but with severe bone marrow suppression and febrile neutropenia, and is considered suitable for patients under 60 in good condition.<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup> The rituximab question remains open: in HOVON 105/ALLG NHL 24, adding rituximab to a methotrexate-based regimen did not demonstrate a significant benefit, which motivated the rituximab-free MIT design.<sup>[21](https://clinicaltrials.gov/study/NCT04514393)</sup> Since late 2023, a zanubrutinib, rituximab, lenalidomide, and temozolomide study in treatment-naïve PCNS DLBCL reported ORR 91.7% and CR 58.3%,<sup>[3](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)</sup> and the registered PRIME-PCNSL trial (NCT07350850) compares pirtobrutinib, sintilimab, rituximab, and methotrexate against standard of care including covalent BTK inhibitor arms; results are not yet available.<sup>[22](https://clinicaltrials.gov/study/NCT07350850)</sup>\n\n## References\n\n1. [Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma (Grommes et al., Blood 2019)](https://pubmed.ncbi.nlm.nih.gov/30567753/)\n2. [NCT02315326 registry entry: Ibrutinib + HD-MTX ± rituximab in newly diagnosed or R/R PCNSL and R/R SCNSL](https://ichgcp.net/clinical-trials-registry/NCT02315326)\n3. [Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up (Frontiers in Oncology, 2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1669385/full)\n4. [Ibrutinib-MTX-rituximab combo shows promise in CNS lymphoma (MDedge, reporting Grommes et al. Blood 2019)](https://ma1.mdedge.com/content/ibrutinib-mtx-rituximab-combo-shows-promise-cns-lymphoma)\n5. [Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma (Lionakis et al., Cancer Cell 2017)](https://www.sciencedirect.com/science/article/pii/S153560817301678)\n6. [High-Dose Methotrexate, Ibrutinib, and Temozolomide in Newly Diagnosed Primary CNS Lymphoma: Multicenter Prospective Phase II Study (Blood Cancer Discovery, 2025)](https://aacrjournals.org/bloodcancerdiscov/article/6/3/191/762115/High-Dose-Methotrexate-Ibrutinib-and-Temozolomide)\n7. [Adding Ibrutinib to R-MVP Drives Deep and Durable Responses in PCNSL (Hematology Advisor, reporting Neuro-Oncology 2026)](https://www.hematologyadvisor.com/news/lymphoma-pcnsl-ibrutinib-rmvp-deep-durable-response-treatment-risk/)\n8. [High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for Newly Diagnosed PCNSL: Multi-Center Prospective Phase II Study (ASH 2023 abstract)](https://ash.confex.com/ash/2023/webprogram/Paper185212.html)\n9. [Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy (Cancer Medicine)](https://www.ovid.com/journals/camed/fulltext/10.1002/cam4.3499~clinical-outcomes-of-newly-diagnosed-primary-cns-lymphoma)\n10. [Christian Grommes and colleagues (2017). Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery.](https://doi.org/10.1158/2159-8290.cd-17-0613)\n11. [Michail S. Lionakis and colleagues (2017). Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell.](https://doi.org/10.1016/j.ccell.2017.04.012)\n12. [Christian Grommes and colleagues (2018). Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood.](https://doi.org/10.1182/blood-2018-09-875732)\n13. [Patrick G. Morris and colleagues (2013). Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.2013.50.4910)\n14. [Yan Gao and colleagues (2025). High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study. Blood Cancer Discovery.](https://doi.org/10.1158/2643-3230.bcd-24-0156)\n15. [Lauren R Schaff and colleagues (2026). Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma. Neuro-Oncology.](https://doi.org/10.1093/neuonc/noag011)\n16. [Marion Alcantara and colleagues (2024). Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. Journal of Hematology & Oncology.](https://doi.org/10.1186/s13045-024-01606-w)\n17. [Ibrutinib monotherapy for relapse or refractory PCNSL and primary vitreoretinal lymphoma: iLOC phase II study (Eur J Cancer 2019)](https://pubmed.ncbi.nlm.nih.gov/31279304/)\n18. [Osnat Bairey and colleagues (2023). A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma. Cancer.](https://doi.org/10.1002/cncr.34985)\n19. [Imbruvica Plus Drug Combo Shows Strong Responses in Newly Diagnosed PCNSL (Cure Today, 2025 SNO Annual Meeting)](https://www.curetoday.com/view/imbruvica-plus-drug-combo-shows-strong-responses-in-newly-diagnosed-pcnsl)\n20. [Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study (Frontiers in Immunology, 2025)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1579483/full)\n21. [NCT04514393: Phase II Study of MIT Regimen (Methotrexate, Ibrutinib, Temozolomide) in Newly Diagnosed PCNSL (ClinicalTrials.gov)](https://clinicaltrials.gov/study/NCT04514393)\n22. [PRIME-PCNSL: Pirtobrutinib, Sintilimab, Rituximab, Methotrexate vs Investigator-Selected Standard of Care in Treatment-Naive PCNSL (NCT07350850)](https://clinicaltrials.gov/study/NCT07350850)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Cancer chemotherapy and regimens › Targeted agent regimens*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n",
 "same_as": [],
 "url": "https://www.edgepedia.org/ibrutinib-regimen",
 "markdown_url": "https://www.edgepedia.org/ibrutinib-regimen.md",
 "license": {
  "name": "Edgepedia Community License 1.0",
  "url": "https://www.edgepedia.org/edgepedia/license",
  "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.",
  "spdx": "LicenseRef-Edgepedia-Community-1.0"
 },
 "credit": "\"Ibrutinib regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/ibrutinib-regimen. Edgepedia Community License 1.0.",
 "credit_md": "\"[Ibrutinib regimen](https://www.edgepedia.org/ibrutinib-regimen)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/ibrutinib-regimen](https://www.edgepedia.org/ibrutinib-regimen). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).",
 "credit_html": "\"<a href=\"https://www.edgepedia.org/ibrutinib-regimen\">Ibrutinib regimen</a>\", Edgepedia (EdgeChat), <a href=\"https://www.edgepedia.org/ibrutinib-regimen\">https://www.edgepedia.org/ibrutinib-regimen</a>. <a href=\"https://www.edgepedia.org/edgepedia/license\">Edgepedia Community License 1.0</a>.",
 "speakable": "The ibrutinib regimen is a combination treatment for primary central nervous system lymphoma in which the BTK inhibitor ibrutinib is given with high-dose methotrexate, usually with rituximab."
}